Compare Illinois Tool Works Inc. (ITW) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs Sana Biotechnology Inc — how do they compare? Illinois Tool Works Inc. trades at $293 (market cap $83.49B), while Sana Biotechnology Inc trades at $3.77 (market cap $1.13B). The key difference: Illinois Tool Works Inc. is far larger — about 73.9× Sana Biotechnology Inc's market cap, and Illinois Tool Works Inc. pays a 2.35% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ITW | SANA | |
|---|---|---|
Market Cap | $83.49B | $1.13B |
Sector | Industrials | Health |
52-Week High | $299.60 | $5.92 |
52-Week Low | $241.07 | $2.68 |
Enterprise Value | $92.34B | $1.05B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $293.66, down 0.29% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 19.39% net income margin and 104.65% ROE, though valuations appear elevated at P/E 26.55 and P/B 28.85. Recent Q2 2026 earnings beat expectations at $2.84 EPS, and management raised full-year guidance amid manufacturing sector recovery. The company announced a 7% dividend increase and $6 billion share repurchase program in August 2026.
Outlook remains positive with analyst consensus target of $314.25 offering 7% upside potential. Key catalysts include continued manufacturing recovery and margin expansion from the 80/20 program. Risks include premium valuation concerns and potential organic sales declines masked by currency gains. Institutional sentiment is mixed with 21% buy ratings versus 32% sell recommendations.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
